One of these studies showed that ER+/HER2+ tumours showed much less suppression of proliferation during AI treatment (Ki67 suppression: 45% vs 89.1%; P = 0.0001), even when a clinical response was observed (Ellis et al. 2006). The gene discussed is ERBB2; the disease is neoplasm.